CoChat
Sign Up
Cited by 1,511

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Age-related macular degeneration

Mitchell, Paul, Liew, Gerald, Gopinath, Bamini, Wong, Tien Y·2018·The Lancet
DOI 10.1016/s0140-6736(18)31550-2
Open this paper in CoChat — free account

Abstract

Age-related macular degeneration is a leading cause of visual impairment and severe vision loss. Clinically, it is classified as early-stage (medium-sized drusen and retinal pigmentary changes) to late-stage (neovascular and atrophic). Age-related macular degeneration is a multifactorial disorder, with dysregulation in the complement, lipid, angiogenic, inflammatory, and extracellular matrix pathways implicated in its pathogenesis. More than 50 genetic susceptibility loci have been identified, of which the most important are in the CFH and ARMS2 genes. The major non-genetic risk factors are smoking and low dietary intake of antioxidants (zinc and carotenoids). Progression from early-stage to late-stage disease can be slowed with high-dose zinc and antioxidant vitamin supplements. Intravitreal anti-vascular endothelial growth factor therapy (eg, ranibizumab, aflibercept, or bevacizumab) is highly effective at treating neovascular age-related macular degeneration, and has markedly decreased the prevalence of visual impairment in populations worldwide. Currently, no proven therapies for atrophic disease are available, but several agents are being investigated in clinical trials. Future progress is likely to be from improved efforts in prevention and risk-factor modification, personalised medicine targeting specific pathways, newer anti-vascular endothelial growth factor agents or other agents, and regenerative therapies.

Overview

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(18)31550-2

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Given that most treatments in development for dry age-related macular degeneration are invasive, an orally delivered small-molecule approach targeting S2R would offer several advantages over these approaches and/or may be a complementary approach in combination with invasive therapeutics if proven efficacious in clinical trials.

    “Given that most of the treatments in development are invasive in nature [45], an orally delivered small-molecule approach targeting S2R would offer several advantages over these approaches and/or may be a complementary approach in combination with invasive therapeutics if proven efficacious in clinical trials.”

    From Sigma-2 Receptors—From Basic Biology to Therapeutic Target: A Focus on Age-Related Degenerative Diseases (2023) · cites this paper as [45]

  • Dry age-related macular degeneration involves a dysregulation of cellular processes, among which is the accumulation of lipid deposits known as drusen that causes a thickening of Bruch's membrane.

    “Dry AMD involves a dysregulation of cellular processes, among which is the accumulation of lipid deposits, known as drusen, that causes a thickening of Bruch’s membrane [45].”

    From Sigma-2 Receptors—From Basic Biology to Therapeutic Target: A Focus on Age-Related Degenerative Diseases (2023) · cites this paper as [45]

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 117

  1. Coleman, 2008, Age-related macular degeneration, Lancet, 372, 1835, 10.1016/S0140-6736(08)61759-6 · DOI · Paper page
  2. Lim, 2012, Age-related macular degeneration, Lancet, 379, 1728, 10.1016/S0140-6736(12)60282-7 · DOI
  3. Wong, 2014, Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis, Lancet Glob Health, 2, e106, 10.1016/S2214-109X(13)70145-1 · DOI
  4. Bourne, 2013, Causes of vision loss worldwide, 1990–2010: a systematic analysis, Lancet Glob Health, 1, e339, 10.1016/S2214-109X(13)70113-X · DOI
  5. Cicinelli, 2018, Optical coherence tomography angiography in dry age-related macular degeneration, Surv Ophthalmol, 63, 236, 10.1016/j.survophthal.2017.06.005 · DOI
  6. Sambhav, 2017, The application of optical coherence tomography angiography in retinal diseases, Surv Ophthalmol, 62, 838, 10.1016/j.survophthal.2017.05.006 · DOI
  7. Schmidt-Erfurth, 2017, A view of the current and future role of optical coherence tomography in the management of age-related macular degeneration, Eye (Lond), 31, 26, 10.1038/eye.2016.227 · DOI
  8. Bird, 1995, An international classification and grading system for age-related maculopathy and age-related macular degeneration, Surv Ophthalmol, 39, 367, 10.1016/S0039-6257(05)80092-X · DOI · Paper page
  9. Ferris, 2013, Clinical classification of age-related macular degeneration, Ophthalmology, 120, 844, 10.1016/j.ophtha.2012.10.036 · DOI
  10. Klein, 2014, Harmonizing the classification of age-related macular degeneration in the three-continent AMD consortium, Ophthalmic Epidemiol, 21, 14, 10.3109/09286586.2013.867512 · DOI
  11. Davis, 2005, The Age-Related Eye Disease Study severity scale for age-related macular degeneration: AREDS Report No. 17, Arch Ophthalmol, 123, 1484, 10.1001/archopht.123.11.1484 · DOI · Paper page
  12. Ferris, 2005, A simplified severity scale for age-related macular degeneration: AREDS Report No. 18, Arch Ophthalmol, 123, 1570, 10.1001/archopht.123.11.1570 · DOI · Paper page
  13. Liew, 2016, Validating the AREDS Simplified Severity Scale of age-related macular degeneration with 5- and 10-year incident data in a population-based sample, Ophthalmology, 123, 1874, 10.1016/j.ophtha.2016.05.043 · DOI
  14. Joachim, 2013, Incidence and progression of geographic atrophy: observations from a population-based cohort, Ophthalmology, 120, 2042, 10.1016/j.ophtha.2013.03.029 · DOI
  15. Zhou, 2016, Pseudodrusen and incidence of late age-related macular degeneration in fellow eyes in the comparison of age-related macular degeneration treatments trials, Ophthalmology, 123, 1530, 10.1016/j.ophtha.2016.02.043 · DOI
  16. Finger, 2014, Reticular pseudodrusen: a risk factor for geographic atrophy in fellow eyes of individuals with unilateral choroidal neovascularization, Ophthalmology, 121, 1252, 10.1016/j.ophtha.2013.12.034 · DOI
  17. Khan, 2016, Differentiating drusen: drusen and drusen-like appearances associated with ageing, age-related macular degeneration, inherited eye disease and other pathological processes, Prog Retin Eye Res, 53, 70, 10.1016/j.preteyeres.2016.04.008 · DOI
  18. Joachim, 2015, The incidence and progression of age-related macular degeneration over 15 years: the Blue Mountains Eye Study, Ophthalmology, 122, 2482, 10.1016/j.ophtha.2015.08.002 · DOI
  19. Colijn, 2017, Prevalence of age-related macular degeneration in Europe: the past and the future, Ophthalmology, 124, 1753, 10.1016/j.ophtha.2017.05.035 · DOI
  20. Cruickshanks, 2017, Generational differences in the 5-year incidence of age-related macular degeneration, JAMA Ophthalmol, 135, 1417, 10.1001/jamaophthalmol.2017.5001 · DOI
  21. Lambert, 2016, Risk factors and biomarkers of age-related macular degeneration, Prog Retin Eye Res, 54, 64, 10.1016/j.preteyeres.2016.04.003 · DOI
  22. Mitchell, 2002, Smoking and the 5-year incidence of age-related maculopathy: the Blue Mountains Eye Study, Arch Ophthalmol, 120, 1357, 10.1001/archopht.120.10.1357 · DOI
  23. Adams, 2012, 20/20—alcohol and age-related macular degeneration: the Melbourne Collaborative Cohort Study, Am J Epidemiol, 176, 289, 10.1093/aje/kws004 · DOI
  24. Shankar, 2007, Association between circulating white blood cell count and long-term incidence of age-related macular degeneration: the Blue Mountains Eye Study, Am J Epidemiol, 165, 375, 10.1093/aje/kwk022 · DOI
  25. Kauppinen, 2016, Inflammation and its role in age-related macular degeneration, Cell Mol Life Sci, 73, 1765, 10.1007/s00018-016-2147-8 · DOI
  26. Casparis, 2017, Surgery for cataracts in people with age-related macular degeneration, Cochrane Database Syst Rev, 2
  27. Cheung, 2014, Is age-related macular degeneration a manifestation of systemic disease? New prospects for early intervention and treatment, J Intern Med, 276, 140, 10.1111/joim.12227 · DOI
  28. Pennington, 2016, Epidemiology of age-related macular degeneration (AMD): associations with cardiovascular disease phenotypes and lipid factors, Eye Vis (Lond), 3, 34, 10.1186/s40662-016-0063-5 · DOI
  29. Kabasawa, 2011, Associations of cigarette smoking but not serum fatty acids with age-related macular degeneration in a Japanese population, Ophthalmology, 118, 1082, 10.1016/j.ophtha.2010.10.012 · DOI
  30. Brody, 2001, Depression, visual acuity, comorbidity, and disability associated with age-related macular degeneration, Ophthalmology, 108, 1893, 10.1016/S0161-6420(01)00754-0 · DOI
  31. Casten, 2013, Update on depression and age-related macular degeneration, Curr Opin Ophthalmol, 24, 239, 10.1097/ICU.0b013e32835f8e55 · DOI
  32. Mitchell, 2006, Quality of life in age-related macular degeneration: a review of the literature, Health Qual Life Outcomes, 4, 97, 10.1186/1477-7525-4-97 · DOI
  33. Gopinath, 2014, Age-related macular degeneration and 5-year incidence of impaired activities of daily living, Maturitas, 77, 263, 10.1016/j.maturitas.2013.12.001 · DOI
  34. Wood, 2011, Risk of falls, injurious falls, and other injuries resulting from visual impairment among older adults with age-related macular degeneration, Invest Ophthalmol Vis Sci, 52, 5088, 10.1167/iovs.10-6644 · DOI
  35. Woo, 2012, Cognitive impairment in age-related macular degeneration and geographic atrophy, Ophthalmology, 119, 2094, 10.1016/j.ophtha.2012.04.026 · DOI
  36. Tsai, 2015, Age-related macular degeneration and risk of degenerative dementia among the elderly in Taiwan: a population-based cohort study, Ophthalmology, 122, 2327, 10.1016/j.ophtha.2015.07.033 · DOI
  37. Keenan, 2014, Associations between age-related macular degeneration, Alzheimer disease, and dementia: record linkage study of hospital admissions, JAMA Ophthalmol, 132, 63, 10.1001/jamaophthalmol.2013.5696 · DOI
  38. McGuinness, 2017, Age-related macular degeneration and mortality: a systematic review and meta-analysis, Ophthalmic Epidemiol, 24, 141, 10.1080/09286586.2016.1259422 · DOI
  39. Fritsche, 2014, Age-related macular degeneration: genetics and biology coming together, Annu Rev Genomics Hum Genet, 15, 151, 10.1146/annurev-genom-090413-025610 · DOI
  40. Cipriani, 2012, Genome-wide association study of age-related macular degeneration identifies associated variants in the TNXB-FKBPL-NOTCH4 region of chromosome 6p21.3, Hum Mol Genet, 21, 4138, 10.1093/hmg/dds225 · DOI
  41. Holliday, 2013, Insights into the genetic architecture of early stage age-related macular degeneration: a genome-wide association study meta-analysis, PLoS One, 8, e53830, 10.1371/journal.pone.0053830 · DOI
  42. Fritsche, 2016, A large genome-wide association study of age-related macular degeneration highlights contributions of rare and common variants, Nat Genet, 48, 134, 10.1038/ng.3448 · DOI · Paper page
  43. Whitmore, 2015, Complement activation and choriocapillaris loss in early AMD: implications for pathophysiology and therapy, Prog Retin Eye Res, 45, 1, 10.1016/j.preteyeres.2014.11.005 · DOI
  44. SanGiovanni, 2014, Clinical applications of age-related macular degeneration genetics, Cold Spring Harb Perspect Med, 4, a017228, 10.1101/cshperspect.a017228 · DOI
  45. Gliem, 2015, Sorsby fundus dystrophy: novel mutations, novel phenotypic characteristics, and treatment outcomes, Invest Ophthalmol Vis Sci, 56, 2664, 10.1167/iovs.14-15733 · DOI · Paper page
  46. Chiu, 2014, A risk score for the prediction of advanced age-related macular degeneration: development and validation in 2 prospective cohorts, Ophthalmology, 121, 1421, 10.1016/j.ophtha.2014.01.016 · DOI
  47. Seddon, 2011, Risk models for progression to advanced age-related macular degeneration using demographic, environmental, genetic, and ocular factors, Ophthalmology, 118, 2203, 10.1016/j.ophtha.2011.04.029 · DOI · Paper page
  48. Buitendijk, 2013, Prediction of age-related macular degeneration in the general population: the Three Continent AMD Consortium, Ophthalmology, 120, 2644, 10.1016/j.ophtha.2013.07.053 · DOI
  49. 2013, Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial, JAMA, 309, 2005, 10.1001/jama.2013.4997 · DOI · Paper page
  50. Seddon, 2011, Smoking, dietary betaine, methionine, and vitamin D in monozygotic twins with discordant macular degeneration: epigenetic implications, Ophthalmology, 118, 1386, 10.1016/j.ophtha.2010.12.020 · DOI
  51. Rudolf, 2008, Prevalence and morphology of druse types in the macula and periphery of eyes with age-related maculopathy, Invest Ophthalmol Vis Sci, 49, 1200, 10.1167/iovs.07-1466 · DOI
  52. Green, 1999, Histopathology of age-related macular degeneration, Mol Vis, 5, 27
  53. Li, 2007, Distribution and composition of esterified and unesterified cholesterol in extra-macular drusen, Exp Eye Res, 85, 192, 10.1016/j.exer.2007.04.002 · DOI
  54. Curcio, 2009, Aging, age-related macular degeneration, and the response-to-retention of apolipoprotein B-containing lipoproteins, Prog Retin Eye Res, 28, 393, 10.1016/j.preteyeres.2009.08.001 · DOI
  55. Sarks, 2007, Relationship of basal laminar deposit and membranous debris to the clinical presentation of early age-related macular degeneration, Invest Ophthalmol Vis Sci, 48, 968, 10.1167/iovs.06-0443 · DOI · Paper page
  56. Freund, 2008, Type 3 neovascularization: the expanded spectrum of retinal angiomatous proliferation, Retina, 28, 201, 10.1097/IAE.0b013e3181669504 · DOI
  57. Yannuzzi, 2001, Retinal angiomatous proliferation in age-related macular degeneration, Retina, 21, 416, 10.1097/00006982-200110000-00003 · DOI
  58. Tsai, 2017, Retinal angiomatous proliferation, Surv Ophthalmol, 62, 462, 10.1016/j.survophthal.2017.01.008 · DOI
  59. Wong, 2016, Age-related macular degeneration and polypoidal choroidal vasculopathy in Asians, Prog Retin Eye Res, 53, 107, 10.1016/j.preteyeres.2016.04.002 · DOI
  60. McLeod, 2009, Relationship between RPE and choriocapillaris in age-related macular degeneration, Invest Ophthalmol Vis Sci, 50, 4982, 10.1167/iovs.09-3639 · DOI
  61. Chew, 2014, Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3, JAMA Ophthalmol, 132, 142, 10.1001/jamaophthalmol.2013.7376 · DOI · Paper page
  62. Ma, 2012, Lutein and zeaxanthin intake and the risk of age-related macular degeneration: a systematic review and meta-analysis, Br J Nutr, 107, 350, 10.1017/S0007114511004260 · DOI · Paper page
  63. Tan, 2008, Dietary antioxidants and the long-term incidence of age-related macular degeneration: the Blue Mountains Eye Study, Ophthalmology, 115, 334, 10.1016/j.ophtha.2007.03.083 · DOI · Paper page
  64. Zhu, 2016, Fish consumption and age-related macular degeneration incidence: a meta-analysis and systematic review of prospective cohort studies, Nutrients, 8, E743, 10.3390/nu8110743 · DOI
  65. Chew, 2013, Long-term effects of vitamins C and E, β-carotene, and zinc on age-related macular degeneration: AREDS report no. 35, Ophthalmology, 120, 1604, 10.1016/j.ophtha.2013.01.021 · DOI
  66. Lawrenson, 2012, Omega 3 fatty acids for preventing or slowing the progression of age-related macular degeneration, Cochrane Database Syst Rev, 11
  67. Heier, 2012, Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration, Ophthalmology, 119, 2537, 10.1016/j.ophtha.2012.09.006 · DOI · Paper page
  68. Martin, 2012, Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results, Ophthalmology, 119, 1388, 10.1016/j.ophtha.2012.03.053 · DOI · Paper page
  69. Kodjikian, 2013, Ranibizumab versus bevacizumab for neovascular age-related macular degeneration: results from the GEFAL noninferiority randomized trial, Ophthalmology, 120, 2300, 10.1016/j.ophtha.2013.06.020 · DOI
  70. Schauwvlieghe, 2016, Comparing the effectiveness of bevacizumab to ranibizumab in patients with exudative age-related macular degeneration. The BRAMD Study, PLoS One, 11, e0153052, 10.1371/journal.pone.0153052 · DOI
  71. Ho, 2014, Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration, Ophthalmology, 121, 2181, 10.1016/j.ophtha.2014.05.009 · DOI
  72. Wykoff, 2015, Prospective trial of treat-and-extend versus monthly dosing for neovascular age-related macular degeneration: TREX-AMD 1-year results, Ophthalmology, 122, 2514, 10.1016/j.ophtha.2015.08.009 · DOI
  73. Berg, 2015, Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol, Ophthalmology, 122, 146, 10.1016/j.ophtha.2014.07.041 · DOI
  74. Li, 2014, Safety and efficacy of conbercept in neovascular age-related macular degeneration: results from a 12-month randomized phase 2 study: AURORA study, Ophthalmology, 121, 1740, 10.1016/j.ophtha.2014.03.026 · DOI
  75. Csaky, 2015, Clinical evaluation of pazopanib eye drops versus ranibizumab intravitreal injections in subjects with neovascular age-related macular degeneration, Ophthalmology, 122, 579, 10.1016/j.ophtha.2014.09.036 · DOI
  76. Yaspan, 2017, Targeting factor D of the alternative complement pathway reduces geographic atrophy progression secondary to age-related macular degeneration, Sci Transl Med, 9, eaaf1443, 10.1126/scitranslmed.aaf1443 · DOI
  77. Jaffe, 2015, Randomized trial to evaluate tandospirone in geographic atrophy secondary to age-related macular degeneration: the GATE study, Am J Ophthalmol, 160, 1226, 10.1016/j.ajo.2015.08.024 · DOI
  78. Yehoshua, 2014, Systemic complement inhibition with eculizumab for geographic atrophy in age-related macular degeneration: the COMPLETE study, Ophthalmology, 121, 693, 10.1016/j.ophtha.2013.09.044 · DOI · Paper page
  79. Michels, 2005, Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study, Ophthalmology, 112, 1035, 10.1016/j.ophtha.2005.02.007 · DOI
  80. Rosenfeld, 2005, Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration, Ophthalmic Surg Lasers Imaging, 36, 331, 10.3928/1542-8877-20050701-14 · DOI
  81. Waldstein, 2016, Morphology and visual acuity in aflibercept and ranibizumab therapy for neovascular age-related macular degeneration in the VIEW trials, Ophthalmology, 123, 1521, 10.1016/j.ophtha.2016.03.037 · DOI
  82. Stoller, 2016, Patterns of early and delayed visual response to ranibizumab treatment for neovascular age-related macular degeneration, JAMA Ophthalmol, 134, 545, 10.1001/jamaophthalmol.2016.0379 · DOI
  83. Johnston, 2017, A retrospective study of ranibizumab treatment regimens for neovascular age-related macular degeneration (nAMD) in Australia and the United Kingdom, Adv Ther, 34, 703, 10.1007/s12325-017-0483-1 · DOI
  84. Berg, 2016, Ranibizumab or bevacizumab for neovascular age-related macular degeneration according to the Lucentis compared to Avastin study treat-and-extend protocol: two-year results, Ophthalmology, 123, 51, 10.1016/j.ophtha.2015.09.018 · DOI
  85. Arnold, 2015, Two-year outcomes of “treat and extend” intravitreal therapy for neovascular age-related macular degeneration, Ophthalmology, 122, 1212, 10.1016/j.ophtha.2015.02.009 · DOI
  86. 2014, The neovascular age-related macular degeneration database: multicenter study of 92 976 ranibizumab injections: report 1: visual acuity, Ophthalmology, 121, 1092, 10.1016/j.ophtha.2013.11.031 · DOI · Paper page
  87. Rofagha, 2013, Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP), Ophthalmology, 120, 2292, 10.1016/j.ophtha.2013.03.046 · DOI · Paper page
  88. Zarranz-Ventura, 2014, The neovascular age-related macular degeneration database: report 2: incidence, management, and visual outcomes of second treated eyes, Ophthalmology, 121, 1966, 10.1016/j.ophtha.2014.04.026 · DOI · Paper page
  89. Bhisitkul, 2016, Fellow eye comparisons for 7-year outcomes in ranibizumab-treated AMD subjects from ANCHOR, MARINA, and HORIZON (SEVEN-UP Study), Ophthalmology, 123, 1269, 10.1016/j.ophtha.2016.01.033 · DOI
  90. Borooah, 2015, Long-term visual outcomes of intravitreal ranibizumab treatment for wet age-related macular degeneration and effect on blindness rates in south-east Scotland, Eye (Lond), 29, 1156, 10.1038/eye.2015.83 · DOI
  91. Johnston, 2016, UK Age-Related Macular Degeneration Electronic Medical Record System (AMD EMR) Users Group Report IV: incidence of blindness and sight impairment in ranibizumab-treated patients, Ophthalmology, 123, 2386, 10.1016/j.ophtha.2016.07.037 · DOI
  92. Holz, 2016, Determinants of visual acuity outcomes in eyes with neovascular AMD treated with anti-VEGF agents: an instrumental variable analysis of the AURA study, Eye (Lond), 30, 1063, 10.1038/eye.2016.90 · DOI
  93. Gillies, 2016, Twelve-month outcomes of ranibizumab vs. aflibercept for neovascular age-related macular degeneration: data from an observational study, Ophthalmology, 123, 2545, 10.1016/j.ophtha.2016.08.016 · DOI
  94. Koh, 2017, Efficacy and safety of ranibizumab with or without verteporfin photodynamic therapy for polypoidal choroidal vasculopathy: a randomized clinical trial, JAMA Ophthalmol, 135, 1206, 10.1001/jamaophthalmol.2017.4030 · DOI
  95. Cheung, 2018, Polypoidal choroidal vasculopathy: definition, pathogenesis, diagnosis, and management, Ophthalmology, 125, 708, 10.1016/j.ophtha.2017.11.019 · DOI
  96. Lee, 2017, Efficacy and safety of intravitreal aflibercept in polypoidal choroidal vasculopathy: 12-month results of the PLANET study, Invest Ophthalmol Vis Sci, 58, 1199
  97. Lee, 2018, Efficacy and safety of intravitreal aflibercept for polypoidal choroidal vasculopathy in the PLANET study: a randomized clinical trial, JAMA Ophthalmol, 10.1001/jamaophthalmol.2018.1804 · DOI
  98. Ueta, 2014, Systemic vascular safety of ranibizumab for age-related macular degeneration: systematic review and meta-analysis of randomized trials, Ophthalmology, 121, 2193, 10.1016/j.ophtha.2014.05.022 · DOI
  99. Yashkin, 2016, Introducing anti-vascular endothelial growth factor therapies for AMD did not raise risk of myocardial infarction, stroke, and death, Ophthalmology, 123, 2225, 10.1016/j.ophtha.2016.06.053 · DOI
  100. Meredith, 2015, Postinjection endophthalmitis in the comparison of age-related macular degeneration treatments trials (CATT), Ophthalmology, 122, 817, 10.1016/j.ophtha.2014.10.027 · DOI
  101. Holz, 2014, Geographic atrophy: clinical features and potential therapeutic approaches, Ophthalmology, 121, 1079, 10.1016/j.ophtha.2013.11.023 · DOI
  102. Kimel, 2016, Functional reading independence (FRI) index: a new patient-reported outcome measure for patients with geographic atrophy, Invest Ophthalmol Vis Sci, 57, 6298, 10.1167/iovs.16-20361 · DOI
  103. Schaal, 2016, Anatomic clinical trial endpoints for nonexudative age-related macular degeneration, Ophthalmology, 123, 1060, 10.1016/j.ophtha.2016.01.034 · DOI
  104. Boyer, 2017, The pathophysiology of geographic atrophy secondary to age-related macular degeneration and the complement pathway as a therapeutic target, Retina, 37, 819, 10.1097/IAE.0000000000001392 · DOI
  105. Holz, 2018, Efficacy and safety of lampalizumab for geographic atrophy due to age-related macular degeneration: Chroma and Spectri Phase 3 randomized clinical trials, JAMA Ophthalmol, 136, 666, 10.1001/jamaophthalmol.2018.1544 · DOI
  106. Strittmatter, 2016, Targeting platelet-derived growth factor receptor β(+) scaffold formation inhibits choroidal neovascularization, Am J Pathol, 186, 1890, 10.1016/j.ajpath.2016.02.018 · DOI
  107. Jaffe, 2016, A phase 1 study of intravitreous E10030 in combination with ranibizumab in neovascular age-related macular degeneration, Ophthalmology, 123, 78, 10.1016/j.ophtha.2015.09.004 · DOI
  108. Jaffe, 2017, Dual antagonism of PDGF and VEGF in neovascular age-related macular degeneration: a phase IIb, multicenter, randomized controlled trial, Ophthalmology, 124, 224, 10.1016/j.ophtha.2016.10.010 · DOI
  109. Dunn, 2017, An overview of the Fovista and Rinucumab trials and the fate of anti-PDGF medications, Ophthalmic Surg Lasers Imaging Retina, 48, 100, 10.3928/23258160-20170130-02 · DOI
  110. Ratnapriya, 2013, Age-related macular degeneration—clinical review and genetics update, Clin Genet, 84, 160, 10.1111/cge.12206 · DOI
  111. Guymer, 2013, Proof of concept, randomized, placebo-controlled study of the effect of simvastatin on the course of age-related macular degeneration, PLoS One, 8, e83759, 10.1371/journal.pone.0083759 · DOI
  112. Miller, 2016, Beyond VEGF-the Weisenfeld lecture, Invest Ophthalmol Vis Sci, 57, 6911, 10.1167/iovs.16-21201 · DOI
  113. Gehlbach, 2015, Statins for age-related macular degeneration, Cochrane Database Syst Rev, 10.1002/14651858.CD006927.pub4 · DOI
  114. MacLaren, 2016, Gene therapy and stem cell transplantation in retinal disease: the new frontier, Ophthalmology, 123, S98, 10.1016/j.ophtha.2016.06.041 · DOI
  115. Constable, 2017, Gene therapy in neovascular age-related macular degeneration: three-year follow-up of a phase 1 randomized dose escalation trial, Am J Ophthalmol, 177, 150, 10.1016/j.ajo.2017.02.018 · DOI · Paper page
  116. Nazari, 2015, Stem cell based therapies for age-related macular degeneration: the promises and the challenges, Prog Retin Eye Res, 48, 1, 10.1016/j.preteyeres.2015.06.004 · DOI
  117. Grzybowski, 2017, Intraocular lenses in age-related macular degeneration, Graefes Arch Klin Exp Ophthalmol, 255, 1687, 10.1007/s00417-017-3740-8 · DOI

Cited by

Sorted by citations

Metadata

Authors
Mitchell, P., Liew, G., Gopinath, B., & Wong, T. Y.
Venue
The Lancet
Publisher
Elsevier BV
Published
2018-09
Volume
392
Issue
10153
Pages
1147-1159
ISSN
0140-6736
DOI
10.1016/s0140-6736(18)31550-2
Cited by
1,511
References
18
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review